Ketty Peris

Active 1996–2025

Also published as
Ketty PERIS
237
Papers
19,038
Citations
76
h-index
210
i10-index

Citations

Citations per year for Ketty Peris1985: 1 citations1992: 1 citations1998: 1 citations1999: 3 citations2000: 7 citations2001: 8 citations2002: 9 citations2003: 7 citations2004: 20 citations2005: 30 citations2006: 29 citations2007: 44 citations2008: 49 citations2009: 52 citations2010: 54 citations2011: 60 citations2012: 79 citations2013: 81 citations2014: 81 citations2015: 88 citations2016: 80 citations2017: 111 citations2018: 130 citations2019: 329 citations2020: 486 citations2021: 654 citations2022: 621 citations2023: 653 citations2024: 1,122 citations2025: 544 citations2026: 12 citations1986–1991: no citations, so these years are not shown1993–1997: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,272 citing papers, 15.9% of this breakdownItaly: 946 citing papers, 11.9% of this breakdownGermany: 578 citing papers, 7.2% of this breakdownUnited Kingdom: 452 citing papers, 5.7% of this breakdownChina: 402 citing papers, 5% of this breakdownSpain: 398 citing papers, 5% of this breakdownFrance: 359 citing papers, 4.5% of this breakdownAustralia: 265 citing papers, 3.3% of this breakdownNetherlands: 219 citing papers, 2.7% of this breakdownAustria: 212 citing papers, 2.7% of this breakdownCanada: 211 citing papers, 2.6% of this breakdownSwitzerland: 189 citing papers, 2.4% of this breakdown
0%15.9%Other 31.1%

Fields

  • Medicine73.9%
  • Biochemistry, Genetics and Molecular Biology11.7%
  • Immunology and Microbiology10.2%
  • Engineering1.4%
  • Computer Science0.8%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Other1.5%

Topics

  • Cutaneous Melanoma Detection and Management10.2%
  • Nonmelanoma Skin Cancer Studies7.6%
  • Dermatology and Skin Diseases7.1%
  • Psoriasis: Treatment and Pathogenesis5.2%
  • AI in cancer detection2.8%
  • Allergic Rhinitis and Sensitization2.8%
  • Other64.3%

Coauthors

All papers

Open in search
  1. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

    Authors: , , , , , , , , , , , , , , , , , , , , , , - British Journal of Dermatology 2020 cited by 595

  2. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2022 cited by 321

  3. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2022 cited by 287

  4. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2019 cited by 590

  5. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Iris Zalaudek, Claus Garbe - European Journal of Cancer 2023 cited by 267

  6. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

    Authors: , , , , , , , , , , , , , , , - JAMA Dermatology 2020 cited by 279

  7. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susana Puig, Frank Seebach, Gavin Thurston, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Timothy G. Bowler, Matthew G. Fury - The Lancet Oncology 2021 cited by 278

  8. Dermoscopy of pigmented skin lesions: Results of a consensus meeting via the Internet

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brian Katz, Robert O. Kenet, Harald Kittler, J. Kreusch, Josep Malvehy, Giampiero Mazzocchetti, Margaret Oliviero, Fezal zdemir, Ketty Peris, Roberto Perotti, Ana M. Perusquia, Maria Antonietta Pizzichetta, Susana Puig, Babar Rao, Pietro Rubegni, Toshiaki Saida, Massimiliano Scalvenzi, Stefania Seidenari, Ignazio Stanganelli, Masaru Tanaka, Karin Westerhoff, Ingrid Wolf, Otto Braun‐Falco, Helmut Kerl, Takeji Nishikawa, Klaus Wolff, Alfred W. Kopf - Journal of the American Academy of Dermatology 2003 cited by 1,204

  9. Pruritus as a Distinctive Feature of Type 2 Inflammation

    Authors: , , , , , - Vaccines 2021 cited by 160

  10. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2020 cited by 320

  11. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

    Authors: , , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2022 cited by 75

  12. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2022 cited by 174

  13. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2020 cited by 240

  14. European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement

    Authors: , , , , , , , , , , , , , , , , , , - Journal of the European Academy of Dermatology and Venereology 2021 cited by 99

  15. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ziad Reguiai, Claire Bernier, Camille Leleu, Julien Seneschal, Delphine Staumont-Sallé, Thomas Hubiche, Caroline Jacobzone, Abdallah Khemis, Marie-Noëlle Crépy, Margitta Worm, Andrea Bauer, Sabine Sell, Swarna Ekanayake-Bohlig, Sylvia Pauser, Timo Buhl, Andreas Schwinn, Bernadette Eberlein, Sven Quist, Boris Bauer, Ketty Peris, Maria Teresa Rossi, Maria Fargnoli, Luigi Naldi, Luca Stingeni, Silvia Ferrucci, Irena Walecka-Herniczek, Dorota Krasowska, Aleksandra Lesiak, Aleksandra Okuniewska, Grażyna Pulka, Malgorzata Dyczek, Bartlomiej Kwiek, Rafal Czajkowski, Hanna Myśliwiec, Padma Mohandas, Sandeep Cliff, Richard Warren, Pippa Cousen, Graham Johnston, Richard Woolf, Kim Papp, David Adam, Darryl Toth, Chih-ho Hong, Irina Turchin, Firouzeh Niakosari, Elena Poulos, Jason Rivers, Jason Ohayon, Melinda Gooderham, Milan Tjioe, Thomas Rustemeyer, Marjolein S. de Bruin-Weller, Marie L.A. Schuttelaar, Judith Molhoek, Bert Oosting, Andreas Pinter, Markus Kaspari, Nina Magnolo, Michael Sebastian, Diamant Thaci, Sibylle Schliemann, Peter Radny, Nicolas Leitz, Athanasios Tsianakas, Amir Yazdi, Maria Kamstrup, Mette Sommerlund, Claus Zachariae, Witold Owczarek and 20 more - The Lancet 2024 cited by 89

  16. Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study

    Authors: , , , , , , , - Clinical Drug Investigation 2021 cited by 87

  17. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

    Authors: , , , , , , , , , , , , , - European Journal of Cancer 2015 cited by 507

  18. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 106

  19. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - American Journal of Clinical Dermatology 2023 cited by 49

  20. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline

    Authors: , , , , , , , , , , , , - European Journal of Cancer 2015 cited by 498

  21. Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*

    Authors: , , , , , , , , , , , , , , , , , , , , , , - British Journal of Dermatology 2020 cited by 172

  22. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2020 cited by 87

  23. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2021 cited by 107

  24. Targeting IL-4 for the Treatment of Atopic Dermatitis

    Authors: , , , - ImmunoTargets and Therapy 2020 cited by 103